Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
NCT06224257Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linperlisib in T-cell large granular lymphocytic leukemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of patients with hematologic remission. Started Dec 2023; status: recruiting.
02
Drugs
linperlisib
03
Conditions
T-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on NCT06224257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224257.